CRT, Tusk and UCL form immuno-oncology pact
Cancer Research Technology, Tusk Therapeutics and UCL (University College London) have have signed a pact to research, develop and commercialise an antibody-based therapeutic against a target known to play a key role in immune suppression in cancer.
Read More
